Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426951 | 1.00 | NLRP3 (0.48) | NLRP3CYP3A4ESR1ESR2CA12 | |
| Hydrochloric Acid SCHEMBL30213942 | 0.98 | NLRP3 (0.47) | NLRP3CYP3A4ESR1ESR2CA12 | |
| SCHEMBL9588894 | 0.92 | RAB9A (0.46) | NLRP3CYP3A4ESR1ESR2CETP | |
| SCHEMBL9588822 | 0.92 | RAB9A (0.46) | NLRP3CYP3A4ESR1ESR2CETP | |
| SCHEMBL9588433 | 0.89 | MAPK14 (0.46) | NLRP3ALDH1A1CETPRAB9A | |
| SCHEMBL1031161 | 0.88 | HSD17B1 (0.52) | NLRP3CYP3A4ESR1ESR2XDH | |
| SCHEMBL1277201 | 0.87 | NLRP3 (0.49) | NLRP3ALDH1A1CETPRAB9A | |
| SCHEMBL9589894 | 0.87 | NLRP3 (0.49) | NLRP3ALDH1A1CETPRAB9A | |
| SCHEMBL9589214 | 0.85 | NLRP3 (0.48) | NLRP3ALDH1A1CETPRAB9A | |
| SCHEMBL3147185 | 0.84 | GPR3 (0.50) | CETPGPR3SLC22A12XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4433480-A1 | HETEROCYCLIC NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-09-25 | — | — | EP | claimed |
| CN-118359751-A | Polymer microsphere using aromatic compound as stabilizer and preparation method thereof | 海南大学 | 2024-07-19 | — | — | CN | claimed |
| EP-4392414-A1 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| CN-118183683-A | Preparation method and application of mesoporous fluorine-doped carbon material | 中国科学院大连化学物理研究所 | 2024-06-14 | — | — | CN | claimed |
| WO-2023088856-A1 | HETEROCYCLIC NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | claimed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| EP-3686198-B1 | MU-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) | 2022-12-14 | — | — | EP | claimed |
| CN-115403570-A | Mu-opioid receptor agonist, preparation method thereof and application thereof in medicine field | 上海华汇拓医药科技有限公司 | 2022-11-29 | — | — | CN | claimed |
| CN-107032965-B | Preparation method of 3-trifluoromethoxyphenol | 金凯(辽宁)化工有限公司 | 2020-04-07 | — | — | CN | claimed |
| US-10029992-B2 | Diaminotriazine compounds and their use as herbicides | BASF SE (DE) | 2018-07-24 | — | — | US | claimed |
| WO-2001077079-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2001068605-A1 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED BENZENES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-09-20 | — | — | WO | claimed |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2001-08-30 | — | — | US | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115695-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115694-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018724-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018723-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| EP-0718280-A2 | Derivatives of beta-aminopropionic acid with a fungicidal activity | ISAGRO RICERCA S.r.l. (IT) | 1996-06-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | NLRP3 545/4885CYP3A4 2162/4885ESR1 3947/4885 |
| US-10029992-B2 | Diaminotriazine compounds and their use as herbicides | NR4A3, CBR3, RCOR3 | NLRP3 2455/4885CYP3A4 2369/4885ESR1 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.